Why the study?
Diabetic patients tend to have increased platelet reactivity after CABG, but the association between HbA1c levels and platelet reactivity and clinical outcomes was unclear.
Does HbA1c level affect platelet reactivity and clinical outcomes in diabetic patients undergoing elective CABG?
Observational (n=225)
Does HbA1c level affect platelet reactivity and clinical outcomes in diabetic patients undergoing elective CABG?
In diabetic patients undergoing CABG, lower HbA1c (<7%) is associated with a higher prevalence of aspirin resistance, though this did not translate to differences in short-term clinical outcomes.
HbA1c does not predict post-CABG outcomes in diabetics; leaves open whether platelet reactivity testing aids risk stratification.
BACKGROUND: Diabetic patients tend to have increased platelet reactivity after coronary artery bypass grafting (CABG). The aim of this study was to determine the association between hemoglobin A1c (HbA1c) values and platelet reactivity and to evaluate the consequent impact on clinical outcomes in patients undergoing CABG. METHODS: This prospective observational trial consecutively enrolled 225 diabetic patients undergoing CABG, between February 2014 and October 2018. HbA1c levels and platelet function (multiple electrode aggregometry [MEA]) were analyzed the day before surgery and on postoperative day 4 (POD 4). Patients were divided into two groups according to the HbA1c value: HBA1c < 7% and HbA1c ≥ 7%. RESULTS: < 0.001). The prevalence of preoperative aspirin resistance (AR) was 46.4% relative to 57.2% after surgery showing consistent increase in postoperative AR by approximately 10%. In addition, the prevalence of AR in the HbA1c < 7% group was higher by 10% compared with the HbA1c ≥ 7% group, both before and after surgery. We did not demonstrate differences in clinical outcomes between the HbA1c groups. CONCLUSION: Perioperative assessment of platelet reactivity in diabetic patients detects those with AR who may be at increased risk of adverse ischemic events. A personalized approach guided by MEA and administration of early and more potent antiaggregation therapy after CABG can be beneficial in this group of patients.
No takes yet. Share an insight, caveat, or question.
Mihaljević et al. (2022) conducted an observational in Diabetes Mellitus undergoing Coronary Artery Bypass Grafting (n=225). HbA1c ≥ 7% vs. HbA1c < 7% was evaluated on Aspirin resistance (AR) and clinical outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: